EXPERT-LEVEL, ACTIONABLE INSIGHTS
RetinAI has developed a set of disease evaluation apps powered by AI to bring expert-level assessment of retinal diseases to everyday patient management.
Our tools generate actionable insights to understand disease activity and biomarkers. RetinAl's apps provide volume of retinal fluids, layer thickness measurements, and identify AMD biomarkers important to enable the right decisions sooner in healthcare.
Despite advances in imaging technology for clinical management, patient disease activity can be missed in vision-threatening conditions. In a real-world study on the clinical management of wet age-related macular degeneration (AMD), disease activity was missed in up to 16.7% of OCT volumes from patients when compared to the reading center performing the same task. These peer-reviewed results outline the potential of undertreating patients in up to 9.7% of visits.
RetinAl's disease evaluation apps accessed via Heidelberg Engineering's AppWay provide expert-level analysis of a patient's Optical Coherence Tomography (OCT) volumes. Results can be generated during the patient's visit to complement evaluation and management of a patient's disease.
These results help to understand disease development and biomarkers and to provide valuable educational tools for patients. Education to patients help them understand and participate in disease management.
RetinAI provides disease evaluation apps for some of the most common vision-threatening diseases in Ophthalmology.
Enhance, Actionable insights can be generated for the following diseases:
Enhanced insights for both dry and wet AMD. Dry AMD is a gradual degeneration of central retinal tissue making up the macula. Wet AMD is characterized by leakage, or bleeding, of abnormal blood vessels under the macula. The dry form of AMD can develop into wet AMD, where the disease and impact of vision loss can progress rapidly.
An eye condition that potentially causes vision loss to patients with diabetes. DR causes damage to the blood vessels of the retina. Different complications may include swelling and leakage of fluid and in other cases, abnormal, new blood vessels growing on the retinal surface.
A serious complication of diabetes where tiny micro-aneurysms protrude the vessels walls, leaking fluid and blood into the retina. This condition may cause swelling (edema) in the macula, leading to vision loss and blindness.
A blockage of the small veins in the retina. This blockage causes blood and fluid to spill into the retina where the macula can swell from this fluid, affecting central vision. Without blood circulation, nerve cells in the eye may die, eventually causing vision loss to patients.
A set of CE-Marked Al models validated and approved for clinical use. These models provide valuable insights for patient management.
Identifies and quantifies the volume of pathological fluid such as intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelium detachment (PED).
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.